Segmented Borrelia Peptide Reagents for Lyme Diagnosis and Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods and tools for diagnosing, treating, and preventing Lyme disease, which is increasingly prevalent and often misdiagnosed, with no commercial vaccines available to protect against Borrelia burgdorferi infection.
Innovation Solution
Development of peptides derived from Borrelia burgdorferi proteins and nucleic acid sequences encoding these peptides for use in diagnostics and pharmaceutical compositions that induce a protective immune response, including a sonicated bacteria vaccine that elicits an antibody-independent protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for Lyme disease, then diagnosis can be performed, but accuracy and reliability are insufficient leading to misdiagnosis
Solution Approach 1:
The diagnostic reagent is segmented into multiple specific peptides (SEQ ID NO: 10-18) derived from different Borrelia burgdorferi proteins, each targeting specific antigenic epitopes. This segmentation allows the system to detect multiple bacterial proteins simultaneously, improving diagnostic accuracy and reducing misdiagnosis by providing more specific and comprehensive detection capabilities.
2Adaptability or versatility
If no commercial vaccines are available, then current prevention options are limited, but this creates a need for effective prophylaxis and treatment solutions
Solution Approach 1:
The patent provides preliminary protective action through peptides and nucleic acid sequences that can be used in vaccines to prevent Borrelia burgdorferi infection before it occurs. The peptides (SEQ ID NO: 10-18) and encoding nucleic acids enable the development of prophylactic vaccines that stimulate protective immune responses, addressing the lack of commercial vaccines and providing reliable prevention capability.
3Productivity
If the incidence of Lyme disease is increasing, then more cases require diagnosis and treatment, but existing methods are insufficient to handle the growing burden
Solution Approach 1:
The diagnostic reagent system serves multiple functions: it detects various stages of Lyme disease infection, identifies different bacterial proteins (OspA, OspC, VlsE, etc.), and can be applied across diverse patient populations. This multi-functionality increases diagnosis and treatment capacity while maintaining high detection accuracy through targeted peptide sequences that recognize specific Borrelia antigens.
Data Source
AI summary
Reagents that include certain identified peptides derived from B. burgdorferi proteins, or nucleic acid sequences encoding same are useful in the diagnosis of Lyme borreliosis (Lyme Disease) in infected subject are disclosed herein. Such reagents can also include nucleic acid sequences encoding the peptides. Pharmaceutical compositions useful for the treatment or prophylaxis of B. burgdorferi infection include certain peptides derived from B. burgdorferi proteins, or nucleic acid sequences encoding same. Methods of treating or preventing Lyme borreliosis (Lyme Disease) include administering effective amount of such pharmaceutical compositions. An antibody independent prophylactic pharmaceutical composition comprises a sonicate of B. burgdorferi bacterium; and methods of treating or preventing Lyme borreliosis include administering effective amounts of that sonicate composition are also disclosed herein.